Narmada macplast drip irrigation Systems Ltd has announced the appointment of Ms. Vidhi Krupal Shah as Company Secretary & Compliance Officer, following the recent resignation of the previous incumbent. The company informed the Bombay Stock Exchange about this development under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Previous Personnel Change

Ms. Hemangi Akshaykumar Vasoya had resigned from her position as Company Secretary & Compliance Officer, effective February 09, 2026. The resignation was due to pre-occupancy in other assignments.

New Appointment Details

The Board of Directors, in its meeting held on February 13, 2026, approved the appointment of Ms. Vidhi Krupal Shah as the new Company Secretary and Compliance Officer. The appointment was made on the recommendation of the Nomination and Remuneration Committee, effective from February 13, 2026.

Professional Profile

Ms. Vidhi Krupal Shah is an Associate member of the Institute of Company Secretaries of India with Membership number A56388. She possesses requisite qualifications and skills in secretarial compliances, regulatory compliance, corporate governance, acquisitions and private equity, and day-to-day legal affairs.

Regulatory Compliance

The appointment was made pursuant to Regulation 6 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 203 of the Companies Act, 2013. The notification was signed by Jiten Vrajlal Vaghasia, Whole-Time Director (DIN: 02433557), confirming adherence to proper corporate governance procedures.

Ms. Shah has provided her formal consent to act as Company Secretary and Compliance Officer, completing all regulatory requirements for the appointment. The company has filed the necessary documentation with BSE Limited under scrip code 517431.

Narmada Macplast Drip Irrigation Systems Limited announced a significant strategic expansion with its Board of Directors approving the acquisition of a controlling 51% stake in GSK Industries Private Limited. The decision was made during a board meeting held on January 23, 2026, marking a key milestone in the company's growth strategy within the irrigation manufacturing sector.

Acquisition Details and Financial Structure

The acquisition involves purchasing 9,34,978 equity shares of ₹10 each at an issue price of ₹390 per share, including a premium of ₹380 per share. The transaction will be executed through cash consideration, with the total investment amounting to ₹364.64 crores.

Target Company Profile and Business Alignment

GSK Industries Private Limited, incorporated on November 2, 2018, operates in the manufacturing sector with a focus on irrigation-related products. The company's business portfolio includes manufacturing of HDPE sprinkler pipes, HDPE drip irrigation pipes, MDPE pipes, and various valves, creating a strong synergy with Narmada Macplast's existing operations.

The target company's comprehensive product range encompasses:

• HDPE and MDPE pipes for irrigation systems
• Sprinkler and drip irrigation components
• PP ball valves and PVC valves
• Agricultural injectors and screen filters
• Plastic ball valves and irrigation fittings

Financial Performance of GSK Industries

GSK Industries has demonstrated varying financial performance over the past three years, with turnover figures showing fluctuations in recent periods.

Strategic Rationale and Expected Impact

The acquisition represents a horizontal integration strategy aimed at expanding Narmada Macplast's manufacturing capabilities beyond its traditional drip irrigation core business. The company expects this move to achieve greater market presence and operational efficiency through:

• Streamlined supply chain operations
• Access to new geographic markets
• Enhanced distribution network capabilities
• Broader industrial manufacturing segments

The transaction is structured as a non-related party acquisition, with no promoter or group company interests in the target entity. No governmental or regulatory approvals are required for completing this acquisition.

Implementation Timeline and Corporate Changes

The acquisition is expected to be completed within 10-12 months from the approval date. Additionally, the board approved a proposal to alter the main object clause of the company by adding new provisions to the Memorandum of Association, reflecting the expanded business scope following the acquisition.

This strategic acquisition positions Narmada Macplast to leverage GSK Industries' established manufacturing capabilities and market presence, potentially strengthening its competitive position in the irrigation and related manufacturing sectors.